Ikaros family zinc finger 1 (IKZF1) is a transcription factor with an important role in controlling the proliferation of hematopoietic and function, particularly lymphoid cell differentiation. It was previously demonstrated that a variety of mechanisms and Ikaros expression patterns associated with various cancers. We hypothesize that aberrant methylation (hypomethylation) of the promoter region IKZF1 probably one of the causes of acute lymphoblastic leukemia B-cells (B-ALL). In the B-ALL patients, increased expression of this gene is a potential cause of B cell differentiation arrest and proliferation induction.
Therefore, as more than 90% of patients with ALL is <15 years, we investigated the promoter methylation patterns IKZF1 in childhood B-ALL.Twenty five newly diagnosed cases of B-ALL included (all younger than 15 years). In addition, we selected 25 children age and sex-matched healthy control group. We collected blood samples in EDTA-containing tubes and lymphocytes were isolated from whole blood using Ficoll 1,077 Lymphosep. Next, we extracted genomic DNA by the method of phenol / chloroform.
Two micrograms of DNA per sample is treated with sodium bisulfite using bisulfite EpiTect Kit, followed by an assessment of DNA methylation by polymerase chain reaction (PCR) analysis of data DNA.Our bisulfite-modified genomic highlighted hypomethylated status of promoter IKZF1 in ALL cases (96% of cases unmethylated).
In contrast, the control group sample partially methylated (68%). This study shows the pattern of the promoter region IKZF1 hypomethylated in childhood B-ALL, which may underlie aberrant patterns of expression of Ikaros previously associated with this malignancy.
An investigation of methylation pattern changes in the IKZF1 promoter in patients with childhood B-cell acute lymphoblastic leukemia.
HDAC6-selective inhibitor synergistically enhances the anticancer activity immunomodulatory drugs in multiple myeloma.
Non-selective histone deacetylase (HDAC) inhibitors have therapeutic effects, but exhibit the dose-limiting toxicities in patients with multiple myeloma (MM). This study examined the interaction between inhibitors of HDAC6, A452, and immunomodulatory drugs (IMiDs) of the dexamethasone (Dex) -sensitive MM cells and resistant compared to current clinically proven HDAC6 inhibitor, ACY-1215.
This suggests that the combination of HDAC6-selective inhibitor, A452, with one of the IMiDs tested (lenalidomide or pomalidomide) causes a synergistic inhibition of cell growth, a decrease in MM cell viability and increased levels of apoptosis. In addition, the enhanced cell death associated with inactivation of AKT and extracellular signal-regulated kinase (ERK) 1/2. Of note, the A452 in combination with synergistically induced MM cytotoxicity IMiDs without changing cereblon expression and thus, downregulation synergistic zinc finger family IKAROS (IKZF) 1/3, c-Myc and interferon regulatory factor 4 (IRF4).
Furthermore, combined with A452 and IMiDs treatment synergistically induced upregulation of PD-L1. More importantly, this combination treatment is effective in Dex-resistant MM cells. Overall, the findings of this study show that the A452 is more effective as an anticancer agent from ACY-1215. Taken together, these findings suggest that the combination of HDAC6-selective inhibitor, A452, and IMiDs may prove useful in the treatment of patients with male patients aged 11 years MM.
An with the removal IKZF1 (Ikaros family zinc finger 1) and positive Breakpoint Regional cluster-C-Abelson oncogene 1 (BCR-ABL1) acute lymphoblastic leukemia developed mucositis, gastrointestinal toxicity, hepatotoxicity, myelosuppression, and severe dermatologic toxicities during the first and second courses of high-dose methotrexate. patients recover fully after treatment.
Description: A sandwich quantitative ELISA assay kit for detection of Human Tachykinin Receptor 1 (TACR1) in samples from tissue homogenates, cell lysates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Tachykinin Receptor 1 (TACR1) in samples from tissue homogenates, cell lysates or other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Tachykinin Receptor 1 (TACR1) in samples from Tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.
However, intracranial hemorrhage (ICH) occurred after oral methotrexate at a dose of 25 mg / m2 in maintenance treatment, and he has a neurological sequelae including paralysis hemiplegia.
